From mid-size pharma to metabolomics platforms, each sector brings its own buyer, its own regulatory logic, and its own reason generic marketing does not work.
A generics manufacturer and a rare disease company may both operate in pharma, but they require distinctly different digital approaches. This section is organised around the specific requirements of each sector, rather than a generic industry overview.
A biotech site is usually written for an investor or scientific partner evaluating credibility before there is a product; a laboratory supplier site is written for a buyer who already knows the specification and just needs fast, accurate confirmation. The same template does not serve both.
See metabolomics and omics and rare disease for how a narrow, technically literate audience is served with genuine depth rather than the same broad pharma messaging diluted down to fit.
What a consumer health / OTC brand can claim directly to a shopper and what a CDMO or CRO can say to a sponsor sit under genuinely different rules — each sector page here starts from the rules that actually apply to it.
See API manufacturers and contract packaging for how a technical buyer checking capacity, certifications and track record is served differently from a marketing-led audience.
See pharma distributors and pharmacy chains for how a high-volume catalogue and multi-location structure are handled without the site becoming unmanageable as the range or footprint grows.
Every industry we build for, each with its own specific approach.
We scope the engagement against the actual combination your company operates in, not a single label from the list above. Most real pharmaceutical companies straddle categories — a mid-size company with one biologic in a CDMO relationship, for example — so the sector pages describe recurring patterns rather than boundaries you need to fit inside exactly.
Tell us your sector directly and we will confirm what relevant work we can show, within whatever confidentiality your projects require. Some sectors we have built for repeatedly; others we have handled once but understand well through adjacent work — we will be specific about which applies before you commit to anything.
No, it reflects the sectors we work in most often, not a complete map of pharmaceutical and life-science verticals. A sector missing from this list does not disqualify you — it usually just means we have built for it less frequently, so we would scope the first conversation around transferable experience from the closest adjacent sector instead.
Yes, because governance and decision-making authority sit differently at each scale. A mid-size company usually has one team making most calls quickly, while a large affiliate answers to a global template it can adapt only within agreed limits. See mid-size pharma and big pharma affiliates for how we structure scope and sign-off around each situation.
Not inherently — the sector itself rarely drives cost. What drives it is content volume, integration complexity, and how many stakeholders need to review and approve each page, all of which vary within a sector as much as between them. See what a pharma website costs for the actual cost drivers we plan against.
Knowing your sector shortens the scoping conversation but does not skip it, since budget, existing systems, and internal review process still need mapping before work begins. For a company that already knows its sector and has decision-makers available, we can usually turn a scope document around within one to two weeks of the first call.
Tell us your specific situation and we will tell you how we would approach it.